MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization

arXiv cs.AI / 4/27/2026

📰 NewsDeveloper Stack & InfrastructureModels & Research

Key Points

  • MolClaw is introduced as an autonomous AI agent for drug molecule evaluation, screening, and optimization, targeting the difficulty agents face when coordinating complex, multi-step tool workflows.
  • The system combines 30+ domain resources using a three-tier hierarchical skill architecture (70 total skills): tool-level atomic operations, workflow-level validated pipeline composition with quality checks and reflection, and discipline-level scientific principles for planning and verification.
  • The paper presents MolBench, a new benchmark covering molecular screening, optimization, and end-to-end discovery tasks that require 8 to 50+ sequential tool calls.
  • MolClaw reportedly achieves state-of-the-art results across metrics, and ablation studies suggest improvements mainly come from structured workflow orchestration rather than ad hoc scripting.
  • The work identifies workflow orchestration as the primary bottleneck limiting AI-driven drug discovery performance in high-complexity scenarios.

Abstract

Computational drug discovery, particularly the complex workflows of drug molecule screening and optimization, requires orchestrating dozens of specialized tools in multi-step workflows, yet current AI agents struggle to maintain robust performance and consistently underperform in these high-complexity scenarios. Here we present MolClaw, an autonomous agent that leads drug molecule evaluation, screening, and optimization. It unifies over 30 specialized domain resources through a three-tier hierarchical skill architecture (70 skills in total) that facilitates agent long-term interaction at runtime: tool-level skills standardize atomic operations, workflow-level skills compose them into validated pipelines with quality check and reflection, and a discipline-level skill supplies scientific principles governing planning and verification across all scenarios in the field. Additionally, we introduce MolBench, a benchmark comprising molecular screening, optimization, and end-to-end discovery challenges spanning 8 to 50+ sequential tool calls. MolClaw achieves state-of-the-art performance across all metrics, and ablation studies confirm that gains concentrate on tasks that demand structured workflows while vanishing on those solvable with ad hoc scripting, establishing workflow orchestration competence as the primary capability bottleneck for AI-driven drug discovery.